NOVA:FRA
Novo Nordisk A/S
34,42 €
arrow_upward
+0,76%(+0,26) 1D
20 ოქტ, 22:00:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NOVA...
Open
33,96 €
High
34,50 €
Low
33,96 €
Mkt. cap
133,92 მლრ.
Avg. vol.
1,12 ათ.
Volume
351,00
52-wk high
54,80 €
52-wk low
30,45 €
No. of employees
67 ათ.
Open
33,96 €
High
34,50 €
Low
33,96 €
Mkt. cap
133,92 მლრ.
Avg. vol.
1,12 ათ.
Volume
351,00
52-wk high
54,80 €
52-wk low
30,45 €
No. of employees
67 ათ.
News stories
From web sources and news partners
TipRanks
·
3 საათის წინ
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data
24/7 Wall St.
·
6 საათის წინ
Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher
Reuters
·
6 საათის წინ
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
Traders Union
·
8 საათის წინ
What's behind Novo Nordisk's latest 2.1% stock surge?
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOმაიკ დუსტარ
Employees66,7 ათ.
Founded1923
HeadquartersBagsværd, დედაქალაქის რეგიონი, დანია
SectorPharmaceutical industry
Websitenovonordisk.com